Genomic predictors and oncogenic drivers in hepatocellular carcinoma
Seventh Framework Programme (FP7-Health 2010)
Heptromic is a 3-year translational research project which aims to solve core problems in the management of hepatocellular carcinoma (HCC), the third most common cause of cancer-related death worldwide.
By defining biomarkers for identification of HCC patients with poor-prognosis and novel genetic or epigenetic drivers Heptromic will achieve the breakthroughs that are critical for developing more personalised therapeutic approaches.
Findings obtained from human tissue samples by applying state-of-the-art technology will be confirmed in sophisticated experimental models and translated into novel biomarkers and targets for high impact clinical use.
Heptromic’s core team comprises leading European researchers in the basic, translational and clinical fields of liver cancer. Our aim is to lay down a foundation for a sustainable network of expertise based on complex, system level, translational research approaches in liver cancer and closely related disease areas. We expect to open up revolutionary new research horizons in liver cancer over the next decade.